Investors
Investor Documents
-
Number of Shares and Vote Rights - April 2021
May 19, 2021 -
2021 Universal Registration Document
April 30, 2021 -
Number of Shares and Vote Rights - March 2021
April 16, 2021 -
Number of Shares and Vote Rights - February 2021
March 19, 2021 -
Number of Shares and Vote Rights - January 2021
February 18, 2021 -
Half-Year Report For Liquidity Contract - December 31, 2020
January 21, 2021 -
Number of Shares and Vote Rights - December 2020
January 21, 2021 -
Number of Shares and Vote Rights - November 2020
December 22, 2020 -
Number of Shares and Vote Rights - October 2020
November 19, 2020 -
Number of Shares and Vote Rights - September 2020
October 20, 2020 -
Half-Year Financial Report 2020
September 30, 2020 -
Number of Shares and Vote Rights - August 2020
September 15, 2020 -
Number of Shares and Vote Rights - July 2020
September 2, 2020 -
Half-Year Report For Liquidity Contract - June 30, 2020
July 21, 2020 -
Number of Shares and Vote Rights - June 2020
July 21, 2020 -
Number of Shares and Vote Rights - May 2020
June 30, 2020 -
2020 Universal Registration Document
May 25, 2020 -
Number of Shares and Vote Rights - April 2020
May 19, 2020 -
Number of Shares and Vote Rights - March 2020
April 15, 2020 -
Number of Shares and Vote Rights - February 2020
March 19, 2020 -
Number of Shares and Vote Rights - January 2020
February 19, 2020 -
Half-Year Report For Liquidity Contract - December 31, 2019
January 23, 2020 -
Number of Shares and Vote Rights - December 2019
January 23, 2020 -
Number of Shares and Vote Rights - November 2019
December 20, 2019 -
Number of Shares and Vote Rights - October 2019
November 19, 2019 -
Number of Shares and Vote Rights - September 2019
October 9, 2019 -
2019 Half-Year Financial Report
September 30, 2019 -
Nombre d’actions composant le capital social et nombre total de droits de vote
September 20, 2019 -
Number of Shares and Vote Rights - July 2019
September 9, 2019 -
Number of Shares and Vote Rights - June 2019
July 17, 2019 -
Half-Year Report For Liquidity Contract - June 30, 2019
July 10, 2019 -
Number of Shares and Vote Rights - May 2019
June 19, 2019 -
Number of Shares and Vote Rights - April 2019
May 20, 2019 -
Number of Shares and Vote Rights - March 2019
May 6, 2019 -
2019 Registration Document
April 30, 2019 -
Number of Shares and Vote Rights - February 2019
March 18, 2019 -
Number of Shares and Vote Rights - January 2019
February 19, 2019 -
2019 Financial Agenda
February 19, 2019 -
Number of Shares and Vote Rights - December 2018
January 17, 2019 -
Half-Year Report For Liquidity Contract - December 31, 2018
January 17, 2019 -
Number of Shares and Vote Rights - November 2018
December 18, 2018 -
Number of Shares and Vote Rights - October 2018
November 16, 2018 -
Number of Shares and Vote Rights - September 2018
October 16, 2018 -
2018 Half-Year Financial Report
September 28, 2018 -
First-Half 2018 Financial Results and Operations Update
September 28, 2018 -
Number of Shares and Vote Rights - August 2018
September 26, 2018 -
Number of Shares and Vote Rights - July 2018
August 31, 2018 -
Half-Year Report for Liquidity Contract - June 30, 2018
July 20, 2018 -
Number of Shares and Vote Rights (June 2018) and 2018 Financial Agenda Update
July 20, 2018 -
Number of Shares and Vote Rights - May 2018
June 19, 2018 -
Number of Shares and Vote Rights - April 2018
May 18, 2018 -
2018 Registration Document
April 30, 2018 -
ABIVAX confirms its eligibility for the PEA-PME system - 2018
April 6, 2018 -
Number of Shares and Vote Rights - March 2018
March 20, 2018 -
2017 Full-Year Results and Progress Report
March 16, 2018 -
Number of Shares and Vote Rights - February 2018
March 15, 2018 -
Number of Shares and Vote Rights - January 2018
February 26, 2018 -
Number of Shares and Vote Rights - December 2017
January 26, 2018 -
Number of Shares and Vote Rights - November 2017
December 18, 2017 -
2018 Financial Agenda
December 15, 2017 -
Number of Shares and Vote Rights - October 2017
November 14, 2017 -
Number of Shares and Vote Rights - September 2017
October 26, 2017 -
2017 Half-Year Financial Report
September 29, 2017 -
First-Half 2017 Financial Results and Update
September 20, 2017 -
ABIVAX receives French Regulatory Approval to Begin Clinical Trial of ABX464 in Ulcerative Colitis
September 20, 2017 -
Number of Shares and Vote Rights - August 2017
September 8, 2017 -
Number of Shares and Vote Rights - July 2017
August 24, 2017 -
Half-Year Report on the Liquidity Contract - June 30, 2017
July 7, 2017 -
Number of Shares and Vote Rights - June 2017
July 7, 2017 -
2017 Registration Document
May 11, 2017 -
Number of Shares and Vote Rights - May 2017
June 9, 2017 -
2016 Registration Document and highlights on the development stage of the portfolio
May 11, 2017 -
Number of Shares and Vote Rights - April 2017
May 11, 2017 -
Number of Shares and Vote Rights - March 2017
April 12, 2017 -
ABIVAX confirms its eligibility for the PEA-PME system - 2017
April 3, 2017 -
2016 Full-Year Results and Progress Report
March 15, 2017 -
Number of Shares and Vote Rights - February 2017
March 13, 2017 -
Number of Shares and Vote Rights - January 2017
February 9, 2017 -
Number of Shares and Vote Rights - December 2016
January 9, 2017 -
Half-Year Report For Liquidity Contract - December 31, 2016
January 9, 2017 -
Number of Shares and Vote Rights - November 2016
December 9, 2016 -
Number of Shares and Vote Rights - October 2016
November 8, 2016 -
Number of Shares and Vote Rights - September 2016
October 10, 2016 -
Corporate update 2016
December 19, 2016 -
2016 Registration Document
December 19, 2016 -
2016 Half Year Financial Results and Corporate Update
September 20, 2016 -
2016 Half-Year Financial Report
September 20, 2016 -
Number of Shares and Vote Rights - August 2016
August 31, 2016 -
Half-year report on the liquidity contract - June 30, 2016
July 6, 2016 -
2015 Full-year Financial Report
June 15, 2016 -
Combined Annual General Meeting: Availability of Supporting Documents - 2016
June 3, 2016 -
Half-Year Report on the Liquidity Contract - December 31, 2015
January 8, 2016 -
2016 Financial Agenda
December 10, 2015 -
2015 Half-Year Results - €57.7 million raised on Euronext and Significant clinical progress on chronic Hepatitis B and HIV/AIDS
September 29, 2015 -
2015 Half-Year Financial Report
September 29, 2015 -
International Offering Memorandum
June 4, 2015 -
ABIVAX Announces the Registration of its Reference Document by AMF
May 19, 2015 -
ABIVAX Launches IPO on the Regulated Market of Euronext in Paris
June 9, 2015 -
Great success of ABIVAX IPO on Euronext Paris, with €57.7 million raised
June 23, 2015